WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
My fiancé died on the morning of our wedding day
Where Baltimore bridge investigation goes now
Olympic champions to earn US$50,000, end of 128
French couple who kept 159 cats banned from keeping pets
DR MARTIN SCURR: How losing your hearing may cause dementia
Five arrested in Taupō on Tuesday after group brawl at Richmond shops
Russia arrests suspected attackers after mass shooting kills 93 at concert
Live: Heavy rain to pummel country's south, orange warnings in place
Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
'We simply cannot afford to': Hawke's Bay leaders desperate for cyclone
How Robert F. Kennedy Jr. could make the first debate stage
Israel: Benjamin Netanyahu protests put political divides back on show